OBJECTIVE: To introduce the research and development of thrombolytic drugs for AMI, and evaluate their clinical efficacy and safety.
目的：介绍急性心肌梗死溶栓药物的研发进展，并评价其临床疗效和安全性。
Thrombolytic therapy is restricted to the time-window, while neuroprotective drugs, despite its unlimited time constraints, are also stuck.
溶栓治疗有时间限制，而无时间限制的神经保护治疗也陷入了困境。
Thrombolytic therapy is restricted to the time-window, while neuroprotective drugs, despite its unlimited time constraints, are also stuck.
溶栓治疗有时间限制，而无时间限制的神经保护治疗也陷入了困境。
应用推荐